GangaGen Biotechnologies receives CARB-X funding to develop Klebicins, a novel protein antibiotic targeting multidrug-resistant Klebsiella pneumoniae lung infections. This addresses a critical need highlighted by the WHO, offering a potential solution to the growing global threat of antimicrobial resistance.
